A Study to Evaluate the Safety, Tolerability, and Effects on Blood and Urine Markers of Single Ascending Dose of GSK4771261 in Healthy Participants and Participants With Autosomal Dominant Polycystic Kidney Disease
NCT ID: NCT06734234
Last Updated: 2025-08-07
Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
RECRUITING
Clinical Phase
PHASE1
Total Enrollment
84 participants
Study Classification
INTERVENTIONAL
Study Start Date
2024-12-11
Study Completion Date
2026-09-04
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
This is a study where a new drug, called GSK4771261 is being tested. Neither the study doctors, study staff or participants will be aware of what treatment is being given. Part A is testing the new study treatment on healthy people. This is to see if it's safe, what it does to the body, and how the body's defense system responds to it. Part B is similar, but the study treatment will be given to people who have a kidney disease called autosomal dominant polycystic kidney disease (ADPKD).
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Renal Impairment Study of PF-06700841
NCT04260464
Healthy Volunteer
Renal Impairment
COMPLETED
PHASE1
A Study to Evaluate the Effects of GLPG2737 in Participants With Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT04578548
Autosomal Dominant Polycystic Kidney Disease
TERMINATED
PHASE2
A Phase I Study to Investigate the Effect of Renal Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD5004
NCT06742762
Renal Impairment
COMPLETED
PHASE1
Evaluate the Efficacy and Safety of ABP-671 in Subjects With Chronic Kidney Disease and Hyperuricaemia
NCT07323095
Chronic Kidney Disease
NOT_YET_RECRUITING
PHASE2
Phase 1 Study to Evaluate the Safety and Tolerability of Intravenously Administered PYC-003
NCT06714006
Autosomal Dominant Polycystic Kidney Disease (ADPKD)
RECRUITING
PHASE1
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Kidney Disease
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Allocation Method
RANDOMIZED
Intervention Model
SEQUENTIAL
This is sequential double-blind study.
Primary Study Purpose
TREATMENT
Blinding Strategy
TRIPLE
Participants
Caregivers
Investigators
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Part A: Cohort 1: Participants receiving GSK4771261 Dose level 1
Healthy participants will be randomized to receive GSK4771261 Dose level 1.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part A: Cohort 2 : Participants receiving GSK4771261 Dose level 2
Healthy participants will be randomized to receive GSK4771261 Dose level 2.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part A: Cohort 3: Participants receiving GSK4771261 Dose level 3
Healthy participants will be randomized to receive GSK4771261 Dose level 3.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part A: Cohort 4: Participants receiving GSK4771261 Dose level 4
Healthy participants will be randomized to receive GSK4771261 Dose level 4.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part A: Cohort 5: Participants receiving GSK4771261 Dose level 5
Healthy participants will be randomized to receive GSK4771261 Dose level 5.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part A: Cohort 6: Participants receiving GSK4771261 Dose level 6
Healthy participants will be randomized to receive GSK4771261 Dose level 6.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part A: Cohort 7 (optional): Participants receiving GSK4771261 Dose level 7
Healthy participants will be randomized to receive GSK4771261 Dose level 7 as the recommendation of Dose escalation committee (DEC).
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part A: Cohort 8 (optional): Participants receiving GSK4771261 Dose level 8
Healthy participants will be randomized to receive GSK4771261 Dose level 8, as per the recommendation from DEC.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part B: Cohort 1: Participants receiving GSK4771261 Dose level 9
Participant with Autosomal dominant polycystic kidney disease (ADPKD) will be randomized to receive GSK4771261 Dose level 9.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part B: Cohort 2: Participants receiving GSK4771261 Dose level 10
Participant with ADPKD will be randomized to receive GSK4771261 Dose level 10.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part B: Cohort 3: Participants receiving GSK4771261 Dose level 11
Participant with ADPKD will be randomized to receive GSK4771261 Dose level11.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part B: Cohort 4 (optional): Participants receiving GSK4771261 Dose level 12
Participant with ADPKD will be randomized to receive GSK4771261 Dose level 12 as the recommendation from DEC.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part B: Cohort 5 (optional): Participants receiving GSK4771261 Dose level 13
Participant with ADPKD will be randomized to receive GSK4771261 Dose level 13, as per the recommendation from DEC.
Group Type
EXPERIMENTAL
GSK4771261
Intervention Type
DRUG
GSK4771261 will be administered.
Part A: Participants receiving Placebo matching GSK4771261
Participants will receive placebo matching GSK4771261
Group Type
PLACEBO_COMPARATOR
Placebo matching GSK4771261
Intervention Type
DRUG
Placebo matching GSK4771261 will be administered.
Part B: Participants receiving placebo matching GSK4771261
Participants will receive placebo matching GSK4771261
Group Type
PLACEBO_COMPARATOR
Placebo matching GSK4771261
Intervention Type
DRUG
Placebo matching GSK4771261 will be administered.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
GSK4771261
GSK4771261 will be administered.
Intervention Type
DRUG
Placebo matching GSK4771261
Placebo matching GSK4771261 will be administered.
Intervention Type
DRUG
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
For Part A
* Body weight greater than or equal to (\>=) 45 kilograms (kg) and basal metabolic index (BMI) within the range 19.5 to 32 kilograms per square meters (kg/m\^2), inclusive
* Capable of giving signed informed consent,
* Participants who are overtly healthy as determined by medical evaluation by the investigator or a medically qualified designee based on medical history, physical examination, laboratory tests, and cardiac monitoring
* Women must be of non-childbearing potential
For Part B (planned Cohorts 1-3 and optional cohorts 4-5):
* Body weight \>=45 kg and BMI within the range 19.5 to 32 kg/m\^2, inclusive.
* Capable of giving signed informed consent, Confirmed diagnosis of Autosomal dominant polycystic kidney disease (ADPKD) by either applicable guidelines and/or genetic and imaging screening assessments
* Participants diagnosed with ADPKD may have complications or comorbidities directly related to ADPKD but should be otherwise healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests clinical testing
* Confirmation of known ADPKD causal genetic mutation(s) at the Polycystic kidney disease (PKD)1 and/or PKD2 loci based on genetic testing at screening and/or existing genetic information collected during the participant's routine clinical care for ADPKD from a genetic testing provider that, in the judgement of the investigator, is clinically valid.
* Mayo imaging classification groups 1C, 1D or 1E as assessed using the information collected at screening
* Estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 45 milliliters per minutes per 1.73 square meters (mL/min/1.73m\^2) (based on the Chronic kidney disease- Epidemiology Collaboration \[CKD-EPI 2021\] eGFR equation) and is not anticipated by the participant's regular treating physician to have a sustained decline by greater than (\>)10 percent (%) over the following 12 months
* Intolerant of tolvaptan treatment, unwilling to initiate tolvaptan treatment or ineligible for tolvaptan treatment for ADPKD
* A female participant is eligible to participate if she is not pregnant or breastfeeding and agrees to use birth control methods as discussed with the study doctor.
* Woman of childbearing potential (WOCBP) and Woman of non-childbearing potential (WONCBP) must have a negative highly sensitive pregnancy test prior to the Magnetic resonance imaging (MRI) scan being performed in the screening period of Part B
* eGFR \>=30 mL/min/1.73m\^2 (based on the CKD-EPI 2021 eGFR equation) and, in the clinical judgement of the investigator, the participant:
* has been clinically stable for the 24 months before screening; and,
* is not anticipated by the participant's regular treating physician to have a sustained decline in kidney function by \>10% over the following 12 months; and,
* is not anticipated to need renal replacement therapy in the next 12 months; and,
* does not have any other clinical, biochemical or familial feature at screening that suggests a clinically significant decline in kidney function is anticipated in the next 12 months.
* Body weight greater than or equal to (\>=) 45 kilograms (kg) and basal metabolic index (BMI) within the range 19.5 to 32 kilograms per square meters (kg/m\^2), inclusive
* Capable of giving signed informed consent,
* Participants who are overtly healthy as determined by medical evaluation by the investigator or a medically qualified designee based on medical history, physical examination, laboratory tests, and cardiac monitoring
* Women must be of non-childbearing potential
For Part B (planned Cohorts 1-3 and optional cohorts 4-5):
* Body weight \>=45 kg and BMI within the range 19.5 to 32 kg/m\^2, inclusive.
* Capable of giving signed informed consent, Confirmed diagnosis of Autosomal dominant polycystic kidney disease (ADPKD) by either applicable guidelines and/or genetic and imaging screening assessments
* Participants diagnosed with ADPKD may have complications or comorbidities directly related to ADPKD but should be otherwise healthy as determined by the investigator or medically qualified designee based on a medical evaluation including medical history, physical examination, laboratory tests clinical testing
* Confirmation of known ADPKD causal genetic mutation(s) at the Polycystic kidney disease (PKD)1 and/or PKD2 loci based on genetic testing at screening and/or existing genetic information collected during the participant's routine clinical care for ADPKD from a genetic testing provider that, in the judgement of the investigator, is clinically valid.
* Mayo imaging classification groups 1C, 1D or 1E as assessed using the information collected at screening
* Estimated glomerular filtration rate (eGFR) greater than or equal to (\>=) 45 milliliters per minutes per 1.73 square meters (mL/min/1.73m\^2) (based on the Chronic kidney disease- Epidemiology Collaboration \[CKD-EPI 2021\] eGFR equation) and is not anticipated by the participant's regular treating physician to have a sustained decline by greater than (\>)10 percent (%) over the following 12 months
* Intolerant of tolvaptan treatment, unwilling to initiate tolvaptan treatment or ineligible for tolvaptan treatment for ADPKD
* A female participant is eligible to participate if she is not pregnant or breastfeeding and agrees to use birth control methods as discussed with the study doctor.
* Woman of childbearing potential (WOCBP) and Woman of non-childbearing potential (WONCBP) must have a negative highly sensitive pregnancy test prior to the Magnetic resonance imaging (MRI) scan being performed in the screening period of Part B
* eGFR \>=30 mL/min/1.73m\^2 (based on the CKD-EPI 2021 eGFR equation) and, in the clinical judgement of the investigator, the participant:
* has been clinically stable for the 24 months before screening; and,
* is not anticipated by the participant's regular treating physician to have a sustained decline in kidney function by \>10% over the following 12 months; and,
* is not anticipated to need renal replacement therapy in the next 12 months; and,
* does not have any other clinical, biochemical or familial feature at screening that suggests a clinically significant decline in kidney function is anticipated in the next 12 months.
Exclusion Criteria
For Part A:
* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data.
* History of malignancy of any type.
* History of kidney disease or kidney abnormalities or eGFR less than (\<) 90 milliliters per minute per 1.73 square meters (mL/min/1.73m\^2) (based on the chronic kidney disease- Epidemiology Collaboration \[CKD-EPI\] 2021 eGFR equation) at screening.
* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study drug and for the duration of study participation.
* QT interval corrected (QTc)\>450 milliseconds (msec)
* Participation in this study would result in loss of blood or blood products in excess of 500 mL within 56 days
* Current enrolment or past participation in an investigational clinical trial in which an investigational medicinal product was administered within the following time periods prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer
* Exposure to more than 4 investigational medicinal products within 12 months prior to dosing
* Significant allergy to humanized monoclonal antibodies
* Clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
* Pregnant or lactating female
* Current or previous diagnosis of diabetes mellites (DM) (Type 1 or Type 2)
* Glycosylated hemoglobin (HbA1c) \>=48 millimoles per mole (mmol/mol) (\>=6.5%) at screening
* Bone fracture within 6 months prior to screening, or presence of a known unresolved or incompletely resolved fracture
* Positive pre-clinical study drug/alcohol screen, including tetrahydrocannabinol
* Positive Human Immunodeficiency Virus (HIV) antibody test
* Evidence of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as determined by local diagnostic procedures
* Evidence at screening of clinically significant hematological disorder (affecting hemoglobin, red blood cells \[RBC\], White blood cells \[WBC\] or platelets) or abnormal blood clotting parameters
* Regular use of recreational drugs, including substances containing tetrahydrocannabinol
* Participants who are unable to refrain from smoking, vaping or using other tobacco products during study visits or overnight stays
* Poor peripheral venous access by visual inspection (intravenous \[IV\] administration cohort(s) only)
* Average weekly intake of greater than (\>) 14 United Kingdom (UK) units of alcohol. One UK unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator \[or medical monitor\], contraindicates participation in the study
* Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.)
* Alanine transaminase (ALT) \>1.5x Upper Limit of Normal (ULN)
* Total bilirubin \>1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \<=3.0xULN as long as direct bilirubin is \<=1.0xULN
* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
* Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention
* Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
* Positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention
Part B:
* Presence of active, clinically significant cardiovascular, respiratory, hepatic, gastrointestinal, endocrine (including, but not limited to, incompletely controlled secondary or tertiary hyperparathyroidism and clinically significant vitamin D deficiency), hematological (including, but not limited to, transfusion-dependent anemia), bone (including, but not limited to, osteoporosis), or neurological disorders, with the exception of ADPKD, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data
* Clinically significant abnormal blood pressure (BP), that is, if the participant is not taking antihypertensive therapy: systolic BP \>=160 millimeters of mercury (mmHg) and/or diastolic BP \>=90mmHg; or If the participant is established on a stable regimen of antihypertensive drug(s): on-treatment systolic BP \>=160 mmHg and/or diastolic BP \>=90mmHg
* Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of recurrence or metastatic disease for 3 years
* Breast cancer within the past 10 years
* Use of prescription and non-prescription drugs, including vitamins A, B, C, E, K, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study drug and for the duration of study participation. Paracetamol, at doses of \<=4 gram per 24 hour (g/24h) is permitted for use at any time during the study
* Contraindication to, or unwillingness to undergo, MRI scanning (e.g., presence of MRI-incompatible metal implant)
* Congenital absence of one kidney
* Kidney cyst interventions such as cyst aspiration or cyst fenestration within 12 weeks prior to screening and during the screening period, or such interventions planned or anticipated within the follow-up period
* Acute symptomatic kidney cyst hemorrhage or infection within 12 weeks prior to screening
* Evidence of current, chronic, or recurrent kidney or liver cyst infection
* Estimated proteinuria \>1g/24 hour at screening and/or pre-dose (day -7 to day -1)
* Abnormal urinalysis suggestive of clinically significant glomerular disease or urinary tract infection
* Presence of known clinically significant renal or hepatic calculi, or symptoms thereof, at screening
* Treatment with tolvaptan within 6 months prior to screening
* Presence of an incompletely healed wound at screening and/or planned surgical procedure that would occur during study.
* Participation in this study would result in loss of blood or blood products in excess of 500 mL within 56 days
* Current enrolment or past participation in an investigational clinical trial in which an investigational medicinal product was administered within the following time periods prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer
* Exposure to more than 4 investigational medicinal products within 12 months prior to dosing
* Significant allergy to humanized monoclonal antibodies
* Clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
* Pregnant or lactating female
* Current or previous diagnosis of diabetes mellites (DM) (Type 1 or Type 2)
* HbA1c \>=48 millimoles per mole (mmol/mol) (\>=6.5%) at screening
* Bone fracture within 6 months prior to screening, or presence of a known unresolved or incompletely resolved fracture
* Positive pre-clinical study drug/alcohol screen, including tetrahydrocannabinol
* Positive HIV antibody test
* Evidence of SARS-CoV-2 infection, as determined by local diagnostic procedures
* Evidence at screening of clinically significant hematological disorder (affecting hemoglobin, RBC, WBC or platelets) or abnormal blood clotting parameters
* Regular use of recreational drugs, including substances containing tetrahydrocannabinol
* Participants who are unable to refrain from smoking, vaping or using other tobacco products during study visits or overnight stays
* Poor peripheral venous access by visual inspection (IV administration cohort(s) only)
* Average weekly intake of greater than (\>) 14 UK units of alcohol. One UK unit is equivalent to 8 grams of alcohol: a half-pint (approximately240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator \[or medical monitor\], contraindicates participation in the study
* Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.)
* Alanine transaminase (ALT) \>1.5x Upper Limit of Normal (ULN)
* Total bilirubin \>1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \<=3.0xULN as long as direct bilirubin is \<=1.0xULN
* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
* Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
* Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
* Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
* QTc \>450 milliseconds (msec) or QTc \>480 msec for participants with bundle branch block
* History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data.
* History of malignancy of any type.
* History of kidney disease or kidney abnormalities or eGFR less than (\<) 90 milliliters per minute per 1.73 square meters (mL/min/1.73m\^2) (based on the chronic kidney disease- Epidemiology Collaboration \[CKD-EPI\] 2021 eGFR equation) at screening.
* Use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study drug and for the duration of study participation.
* QT interval corrected (QTc)\>450 milliseconds (msec)
* Participation in this study would result in loss of blood or blood products in excess of 500 mL within 56 days
* Current enrolment or past participation in an investigational clinical trial in which an investigational medicinal product was administered within the following time periods prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer
* Exposure to more than 4 investigational medicinal products within 12 months prior to dosing
* Significant allergy to humanized monoclonal antibodies
* Clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
* Pregnant or lactating female
* Current or previous diagnosis of diabetes mellites (DM) (Type 1 or Type 2)
* Glycosylated hemoglobin (HbA1c) \>=48 millimoles per mole (mmol/mol) (\>=6.5%) at screening
* Bone fracture within 6 months prior to screening, or presence of a known unresolved or incompletely resolved fracture
* Positive pre-clinical study drug/alcohol screen, including tetrahydrocannabinol
* Positive Human Immunodeficiency Virus (HIV) antibody test
* Evidence of Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, as determined by local diagnostic procedures
* Evidence at screening of clinically significant hematological disorder (affecting hemoglobin, red blood cells \[RBC\], White blood cells \[WBC\] or platelets) or abnormal blood clotting parameters
* Regular use of recreational drugs, including substances containing tetrahydrocannabinol
* Participants who are unable to refrain from smoking, vaping or using other tobacco products during study visits or overnight stays
* Poor peripheral venous access by visual inspection (intravenous \[IV\] administration cohort(s) only)
* Average weekly intake of greater than (\>) 14 United Kingdom (UK) units of alcohol. One UK unit is equivalent to 8 grams (g) of alcohol: a half-pint (approximately 240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator \[or medical monitor\], contraindicates participation in the study
* Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.)
* Alanine transaminase (ALT) \>1.5x Upper Limit of Normal (ULN)
* Total bilirubin \>1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \<=3.0xULN as long as direct bilirubin is \<=1.0xULN
* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
* Presence of hepatitis B surface antigen (HBsAg) and/or hepatitis B core antibody (HBcAb) at screening or within 3 months prior to first dose of study intervention
* Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
* Positive hepatitis C Ribonucleic acid (RNA) test result at screening or within 3 months prior to first dose of study intervention
Part B:
* Presence of active, clinically significant cardiovascular, respiratory, hepatic, gastrointestinal, endocrine (including, but not limited to, incompletely controlled secondary or tertiary hyperparathyroidism and clinically significant vitamin D deficiency), hematological (including, but not limited to, transfusion-dependent anemia), bone (including, but not limited to, osteoporosis), or neurological disorders, with the exception of ADPKD, capable of significantly altering the absorption, metabolism, or elimination of drugs; constituting a risk when taking the study drug; or interfering with the interpretation of data
* Clinically significant abnormal blood pressure (BP), that is, if the participant is not taking antihypertensive therapy: systolic BP \>=160 millimeters of mercury (mmHg) and/or diastolic BP \>=90mmHg; or If the participant is established on a stable regimen of antihypertensive drug(s): on-treatment systolic BP \>=160 mmHg and/or diastolic BP \>=90mmHg
* Lymphoma, leukemia, or any malignancy within the past 5 years except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of recurrence or metastatic disease for 3 years
* Breast cancer within the past 10 years
* Use of prescription and non-prescription drugs, including vitamins A, B, C, E, K, herbal and dietary supplements (including St John's Wort) within 7 days or 5 half-lives (whichever is longer) prior to the first dose of study drug and for the duration of study participation. Paracetamol, at doses of \<=4 gram per 24 hour (g/24h) is permitted for use at any time during the study
* Contraindication to, or unwillingness to undergo, MRI scanning (e.g., presence of MRI-incompatible metal implant)
* Congenital absence of one kidney
* Kidney cyst interventions such as cyst aspiration or cyst fenestration within 12 weeks prior to screening and during the screening period, or such interventions planned or anticipated within the follow-up period
* Acute symptomatic kidney cyst hemorrhage or infection within 12 weeks prior to screening
* Evidence of current, chronic, or recurrent kidney or liver cyst infection
* Estimated proteinuria \>1g/24 hour at screening and/or pre-dose (day -7 to day -1)
* Abnormal urinalysis suggestive of clinically significant glomerular disease or urinary tract infection
* Presence of known clinically significant renal or hepatic calculi, or symptoms thereof, at screening
* Treatment with tolvaptan within 6 months prior to screening
* Presence of an incompletely healed wound at screening and/or planned surgical procedure that would occur during study.
* Participation in this study would result in loss of blood or blood products in excess of 500 mL within 56 days
* Current enrolment or past participation in an investigational clinical trial in which an investigational medicinal product was administered within the following time periods prior to the first dosing day of the current study: 30 days, 5 half-lives or twice the duration of the biological effect of the investigational product, whichever is longer
* Exposure to more than 4 investigational medicinal products within 12 months prior to dosing
* Significant allergy to humanized monoclonal antibodies
* Clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear Immunoglobulin A (IgA) dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis)
* Pregnant or lactating female
* Current or previous diagnosis of diabetes mellites (DM) (Type 1 or Type 2)
* HbA1c \>=48 millimoles per mole (mmol/mol) (\>=6.5%) at screening
* Bone fracture within 6 months prior to screening, or presence of a known unresolved or incompletely resolved fracture
* Positive pre-clinical study drug/alcohol screen, including tetrahydrocannabinol
* Positive HIV antibody test
* Evidence of SARS-CoV-2 infection, as determined by local diagnostic procedures
* Evidence at screening of clinically significant hematological disorder (affecting hemoglobin, RBC, WBC or platelets) or abnormal blood clotting parameters
* Regular use of recreational drugs, including substances containing tetrahydrocannabinol
* Participants who are unable to refrain from smoking, vaping or using other tobacco products during study visits or overnight stays
* Poor peripheral venous access by visual inspection (IV administration cohort(s) only)
* Average weekly intake of greater than (\>) 14 UK units of alcohol. One UK unit is equivalent to 8 grams of alcohol: a half-pint (approximately240 mL) of beer, 1 glass (125 mL) of wine or 1 (25 mL) measure of spirits
* Sensitivity to any of the study interventions, or components thereof, or drug or other allergy that, in the opinion of the investigator \[or medical monitor\], contraindicates participation in the study
* Use of any products intended to treat medical conditions that are not approved by the governing health authority in a given country or region (for example, herbal medicine, health supplements, traditional medicine, homeopathic remedies, etc.)
* Alanine transaminase (ALT) \>1.5x Upper Limit of Normal (ULN)
* Total bilirubin \>1.5xULN; Participants with Gilbert's syndrome can be included with total bilirubin \<=3.0xULN as long as direct bilirubin is \<=1.0xULN
* Current or chronic history of liver disease or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones)
* Presence of HBsAg and/or HBcAb at screening or within 3 months prior to first dose of study intervention
* Positive hepatitis C antibody test result at screening or within 3 months prior to first dose of study intervention
* Positive hepatitis C RNA test result at screening or within 3 months prior to first dose of study intervention
* QTc \>450 milliseconds (msec) or QTc \>480 msec for participants with bundle branch block
Minimum Eligible Age
25 Years
Maximum Eligible Age
65 Years
Eligible Sex
ALL
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
GlaxoSmithKline
INDUSTRY
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
GSK Clinical Trials
Role: STUDY_DIRECTOR
GlaxoSmithKline
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
GSK Investigational Site
Brussels, , Belgium
Site Status
RECRUITING
GSK Investigational Site
Leuven, , Belgium
Site Status
RECRUITING
GSK Investigational Site
London, Ontario, Canada
Site Status
RECRUITING
GSK Investigational Site
Montreal, Quebec, Canada
Site Status
RECRUITING
GSK Investigational Site
Brest, , France
Site Status
RECRUITING
GSK Investigational Site
Cologne, North Rhine-Westphalia, Germany
Site Status
RECRUITING
GSK Investigational Site
Barcelona, , Spain
Site Status
RECRUITING
GSK Investigational Site
Barcelona, , Spain
Site Status
RECRUITING
GSK Investigational Site
Madrid, , Spain
Site Status
RECRUITING
GSK Investigational Site
Madrid, , Spain
Site Status
RECRUITING
GSK Investigational Site
Cambridge, , United Kingdom
Site Status
RECRUITING
GSK Investigational Site
Exeter, , United Kingdom
Site Status
RECRUITING
GSK Investigational Site
London, , United Kingdom
Site Status
RECRUITING
GSK Investigational Site
Newcastle upon Tyne, , United Kingdom
Site Status
RECRUITING
Countries
Review the countries where the study has at least one active or historical site.
Belgium
Canada
France
Germany
Spain
United Kingdom
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2024-516095-15
Identifier Type: OTHER
Identifier Source: secondary_id
221362
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
A Study to Evaluate the Safety and Efficacy of AZD5718 in Participants With Proteinuric Chronic Kidney Disease
NCT04492722
TERMINATED
PHASE2
A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants
NCT07022119
RECRUITING
PHASE1
Study on Efficacy and Safety of LNP023 in C3 Glomerulopathy Patients Transplanted and Not Transplanted
NCT03832114
COMPLETED
PHASE2
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
NCT05213624
COMPLETED
PHASE2
A Study to Evaluate the Blood Levels, Safety, and Tolerability of PF-00734200 in Subjects With Impaired Kidney Function and Normal Kidney Function
NCT00596518
COMPLETED
PHASE1
Efficacy, Safety and Tolerability of Balcinrenone/Dapagliflozin Compared to Dapagliflozin in Adults With Chronic Kidney Disease
NCT06350123
COMPLETED
PHASE2
Study to Investigate the Effects of AZD6140 in Patients With Renal Impairment and in Healthy Volunteers
NCT00733265
COMPLETED
PHASE1
Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of INCB054707 in Participants With Normal and Impaired Renal Function and Participants on Hemodialysis
NCT05624723
COMPLETED
PHASE1
Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Effect on Renal Potassium Clearance
NCT01237899
COMPLETED
PHASE1
A Renal Impairment Study for PF-04965842
NCT03660241
COMPLETED
PHASE1
A Single Dose Study Investigating the Elimination as Well as the Tolerability of PD 0332334 in Healthy Subjects as Compared to Patients With Impaired Kidney Function.
NCT00721422
TERMINATED
PHASE1
A Study of Enlicitide Chloride (MK-0616 Oral PCSK9 Inhibitor) in Participants With Moderate Renal Impairment (MK-0616-007)
NCT05070390
COMPLETED
PHASE1
Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW)
NCT07161037
RECRUITING
PHASE2
Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females
NCT00787618
TERMINATED
PHASE1/PHASE2
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) (2) [Extension of Study 156-05-002]
NCT01022424
COMPLETED
PHASE3
Trial of JMKX003142 in Participants With Rapidly Progressive Autosomal Dominant Polycystic Kidney Disease (ADPKD)
NCT06800651
RECRUITING
PHASE2
A Study to Learn How the Body Processes the Study Medicine PF-07328948 in People With Reduced Kidney Function
NCT07315360
NOT_YET_RECRUITING
PHASE1
Clinical Study of KHK7791 in Hyperphosphatemia Patients on Hemodialysis
NCT04767581
COMPLETED
PHASE3
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
NCT00730145
COMPLETED
PHASE1
Study to Assess the Safety and Pharmacokinetics of AKB-6548 in Participants With Chronic Kidney Disease (CKD), Stages 3 and 4
NCT04707573
COMPLETED
PHASE2
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of HSK21542 Injection in Subjects Undergoing Hemodialysis
NCT04470154
COMPLETED
PHASE2
Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis
NCT03710291
TERMINATED
PHASE3
Safety and Tolerance of Increased Doses of HRS-1780 Tablets in Healthy Subjects
NCT05638126
UNKNOWN
PHASE1
A Long-term Administration Study of OPC-41061 in Patients With Autosomal Dominant Polycystic Kidney Disease (ADPKD) [Extension of Study 156-04-001]
NCT00841568
COMPLETED
PHASE2
A Study of RGLS8429 in Patients With Autosomal Dominant Polycystic Kidney Disease
NCT05521191
COMPLETED
PHASE1